Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-5635 + pegylated interferon alfa
- Development stage
- Unknown
- Lead developer
- Fujian Shengdi Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
HRS-5635 + pegylated interferon alfa is a combination therapy being developed by Fujian Shengdi Pharmaceutical, a subsidiary of Hengrui Pharma, for the treatment of chronic hepatitis B. HRS-5635 is a liver-targeted small interfering RNA (siRNA) designed to silence hepatitis B virus (HBV) gene expression by targeting viral RNA transcripts, thereby reducing the production of viral proteins such as HBsAg. Pegylated interferon alfa (Peg-IFN-α) is an immunomodulatory agent that enhances the host immune response and induces an antiviral state by binding to Type I interferon receptors. This combination is currently being evaluated in Phase II clinical trials, specifically in patients who are virologically suppressed on nucleoside or nucleotide analogues, with the goal of achieving a functional cure for chronic hepatitis B.
- Other names
- HRS-5635 Injection + Peg-IFN-αHRS-5635 Injection + pegylated interferon alfa
02
Targets
HBV RNA (Hepatitis B virus RNA)ASGPR (Asialoglycoprotein Receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on HRS-5635 + pegylated interferon alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-5635 + pegylated interferon alfa.